Document Detail

Hemolytic anemia associated with intravenous immunoglobulin.
MedLine Citation:
PMID:  9270670     Owner:  NLM     Status:  MEDLINE    
Intravenous immunoglobulin (IVIg) is a useful tool in the treatment of a variety of neuromuscular disorders. Though IVIg therapy is generally safe, hemolytic anemia is a potentially serious complication that is often overlooked, and is currently not listed in product inserts. We analyzed 45 patients who received IVIg therapy, including 38 consecutive patients who received IVIg over a 13-month period. On 42 patients, direct antiglobulin testing was performed, searching for antibodies to the patients' own blood type. Of these 42 patients, 12 developed passive sensitization with antibodies to their own blood group antigens after receiving IVIg. Of these 12 patients, 11 patients developed hemolysis severe enough to lower the hemoglobin level by at least 1 g/dL. Of these patients, 3 required blood transfusion, and 1 had IVIg therapy truncated because of the hemolysis. Antibodies to blood group antigens are found in all commercial preparations of IVIg. Though most patients do not have clinically significant hemolysis, clinicians should be aware of this potentially serious complication. Careful monitoring of hemoglobin levels during IVIg therapy is recommended.
J R Wilson; H Bhoopalam; M Fisher
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Muscle & nerve     Volume:  20     ISSN:  0148-639X     ISO Abbreviation:  Muscle Nerve     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-09-17     Completed Date:  1997-09-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7803146     Medline TA:  Muscle Nerve     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1142-5     Citation Subset:  IM    
Department of Neurology #127, Hines VA Hospital, IL 60141, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Hemolytic / etiology*
Antibodies, Anti-Idiotypic / analysis
Autoimmune Diseases / therapy
Immunoglobulins / deficiency
Immunoglobulins, Intravenous / adverse effects*
Neuromuscular Diseases / therapy
Peripheral Nervous System Diseases / therapy
Prospective Studies
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Immunoglobulins; 0/Immunoglobulins, Intravenous

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis.
Next Document:  Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy i...